Tech Company Financing Transactions
AltheaDx Funding Round
On 12/14/2015, AltheaDx announced $30 million in Series C funding from WuXi PharmaTech, Ally Bridge Group and ALMA Life Sciences.
Transaction Overview
Company Name
Announced On
12/14/2015
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Proceeds Purpose
This investment will enable the company to invest in prospective outcome trials for its IDgenetix testing portfolio and expand its commercial capabilities. The Series C financing will also provide capital for product enhancements, international opportunities as well as other investments in long-term growth.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10578 Science Center Dr. 100
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
AltheaDx provides molecular biomarker discovery, assay development and validation, clinical trial testing and companion diagnostics development services.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Nikodem
Chief Operating Officer
Feng Cao
Browse more venture capital transactions:
Prev: 12/14/2015: Reklaim venture capital transaction
Next: 12/14/2015: Arterys venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs